Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Alexander N ShoushtariWalid K ChatilaArshi AroraFrancisco Sanchez-VegaHavish S KanthetiJorge A Rojas ZamalloaPenina KriegerMargaret K CallahanAllison Betof WarnerMichael A PostowParisa MomtazSuresh NairCharlotte E AriyanChristopher A BarkerMary Susan BradyDaniel G CoitNeal X RosenPaul B ChapmanKlaus J BusamDavid B SolitKatherine S PanageasJedd D WolchokNikolaus SchultzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Targeted capture multigene sequencing can detect oncogenic RTK-RAS-MAPK pathway alterations in almost all cutaneous and unknown primary melanomas. TTF of PD-1 monotherapy varies by mechanism of ERK activation. Oncogenic kinase fusions can be successfully targeted in immune checkpoint inhibitor-refractory melanoma.